08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On August 9, 2019, Illinois Governor J.B. Pritzker enacted sweeping changes to the landscape of empl...
Read More >
With the New Year comes changes in many state and federal wage and hour laws. Do you operate in a st...
Read More >
The California Legislature has enacted strict requirements regulating the content that appears on em...
Read More >
The National Institute for Occupational Safety and Health (NIOSH) is scheduled to publish a Federal ...
Read More >
There are few things more fundamental to the sell-side private equity deal practice than, to the max...
Read More >
Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance relat...
Read More >